AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27866177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice (4 oz daily for 6 months)
Number of subjects: 55
Study 27866177 — intervention group
Group type: COMPARATOR
Intervention: Placebo juice (for 6 months)
Number of subjects: 55
Study 25518299 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular running 4‐0 Poliglecaprone 25 (Monocryl)
Number of subjects: 80
Study 25518299 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular running 4‐0 Polydioxanone (PDS)
Number of subjects: 80
Study 25518299 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular running 4‐0 Poliglecaprone 25 (Monocryl) and running horizontal mattress 6‐0 Nylon
Number of subjects: 80
Study 25518299 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular running 4‐0 Polydioxanone (PDS) and running horizontal mattress 6‐0 Nylon
Number of subjects: 80
Study 25518299 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 80
Study 22816441 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,600‐nm carbon dioxide laser
Number of subjects: 12
Study 22816441 — intervention group
Group type: EXPERIMENTAL
Intervention: 2790‐nm yttrium scandium gallium garnet laser
Number of subjects: 12
Study 22816441 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all devices
Number of subjects: 12
Study 22816441 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study 20022264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous treprostinil
Number of subjects: 44
Study 20022264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 18536066 — intervention group
Group type: EXPERIMENTAL
Intervention: WSKY capsule added on risperidone
Number of subjects: 200
Study 18536066 — intervention group
Group type: COMPARATOR
Intervention: Placebo added on risperidone
Number of subjects: 200
Study 15572397 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective dosimetry using FISH translocations for patients with lower earlier dose estimates (up to about 3 Gy)
Number of subjects: 10
Study 15572397 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective dosimetry using FISH translocations for patients with higher earlier dose estimates (up to about 12 Gy)
Number of subjects: 10
Study 15572397 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated chromosomal examinations during the follow-up period
Number of subjects: 10
Study 15572397 — intervention group
Group type: EXPERIMENTAL
Intervention: First phase of decline in dicentric frequencies
Number of subjects: 10
Study 15572397 — intervention group
Group type: EXPERIMENTAL
Intervention: Second phase of decline in dicentric frequencies
Number of subjects: 10
Study 15572397 — intervention group
Group type: EXPERIMENTAL
Intervention: Dicentric levels 10-13 years later
Number of subjects: 10
Study 14651349 — intervention group
Group type: EXPERIMENTAL
Intervention: 201Tl pelvic SPECT imaging in prostate cancer patients
Number of subjects: 25
Study 14651349 — intervention group
Group type: COMPARATOR
Intervention: 201Tl pelvic SPECT imaging in benign prostatic hyperplasia patients
Number of subjects: 25
Study 10471984 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 400 mg three times daily for 2 weeks
Number of subjects: 12
Study 10471984 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin 100 mg three times daily for 2 weeks
Number of subjects: 12
Study 8560996 — intervention group
Group type: EXPERIMENTAL
Intervention: Minprostin gel (0.5 mg intracervical Gel)
Number of subjects: 208
Study 8560996 — intervention group
Group type: EXPERIMENTAL
Intervention: Minprostin tablets (3 mg vaginal tablets)
Number of subjects: 208
Study 8478315 — intervention group
Group type: EXPERIMENTAL
Intervention: Dirithromycin (two 250 mg tablets, once daily)
Number of subjects: 553
Study 8478315 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (four 250 mg tablets, four times daily)
Number of subjects: 553
Study 8478315 — intervention group
Group type: EXPERIMENTAL
Intervention: Dirithromycin
Number of subjects: 553
Study 8478315 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 553
Study 8478315 — intervention group
Group type: EXPERIMENTAL
Intervention: Dirithromycin and Erythromycin
Number of subjects: 553
Study 3563255 — intervention group
Group type: EXPERIMENTAL
Intervention: Theostat 200
Number of subjects: 10
Study 3563255 — intervention group
Group type: COMPARATOR
Intervention: Theodur 200
Number of subjects: 10
Study 29584917 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray
Number of subjects: 43
Study 29584917 — intervention group
Group type: COMPARATOR
Intervention: Tobacco withdrawal
Number of subjects: 43
Study 29254080 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-mg telmisartan (Micardis)
Number of subjects: 60
Study 29254080 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-mg telmisartan (Micardis)
Number of subjects: 60
Study 29254080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 27117283 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS after rTMS
Number of subjects: 23
Study 27117283 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label tDCS
Number of subjects: 23
Study 27117283 — intervention group
Group type: COMPARATOR
Intervention: Real tDCS
Number of subjects: 23
Study 24257146 — intervention group
Group type: EXPERIMENTAL
Intervention: Subfascial catheter with continuous levobupivacaine infusion (Group S)
Number of subjects: 50
Study 24257146 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia with continuous levobupivacaine infusion (Group E)
Number of subjects: 50
Study 24952282 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip-Hop to Health (HH) intervention delivered by peer educators through EFNEP and SNAP-Ed programs
Number of subjects: 0
Study 24952282 — intervention group
Group type: COMPARATOR
Intervention: Standard EFNEP and SNAP-Ed nutrition education curriculum
Number of subjects: 0
Study 23109696 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP45 (45-Gy RT for 5 weeks with concurrent capecitabine)
Number of subjects: 598
Study 23109696 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPOX50 (50-Gy RT for 5 weeks with concurrent capecitabine and oxaliplatin)
Number of subjects: 598
Study 23109696 — intervention group
Group type: COMPARATOR
Intervention: CAP45
Number of subjects: 598
Study 23109696 — intervention group
Group type: COMPARATOR
Intervention: CAPOX50
Number of subjects: 598
Study 19056642 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD) supplemented with virgin olive oil or nuts
Number of subjects: 721
Study 19056642 — intervention group
Group type: COMPARATOR
Intervention: Low-fat control diet
Number of subjects: 721
Study 18088035 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous physical training (4 to 5 times weekly for 6 months)
Number of subjects: 48
Study 18088035 — intervention group
Group type: COMPARATOR
Intervention: No regular physical training
Number of subjects: 48
Study 15571617 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy
Number of subjects: 36
Study 15571617 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 36
Study 15571617 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 36
Study 12206448 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR 300 mg/day (150 mg b.i.d.)
Number of subjects: 70
Study 12206448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 9405728 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist treatment for 6 months
Number of subjects: 28
Study 8949572 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous GH infusion (0.03 microgram (0.1 mU/kg/min) for 39 hours)
Number of subjects: 10
Study 8949572 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous GH infusion (0.03 microgram (0.1 mU/kg/min) for 39 hours)
Number of subjects: 10
Study 8949572 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous GH infusion
Number of subjects: 10
Study 8949572 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous GH infusion
Number of subjects: 10
Study 8949572 — intervention group
Group type: EXPERIMENTAL
Intervention: GH administration (both routes)
Number of subjects: 10
Study 8949572 — intervention group
Group type: EXPERIMENTAL
Intervention: Both routes of GH administration
Number of subjects: 10